Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Blood drug"'
Autor:
Maria O. Vannozzi, Maurizio Nicodemo, Gianluca Damonte, Andrea Armirotti, Marco Venturini, Lucia Cavallini, Gianluigi Lunardi
Publikováno v:
Clinical Therapeutics. 31:1812-1819
Background: Intravenous temsirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is approved for the treatment of advanced renal cell carcinoma (RCC). Sirolimus, the principal metabolite of temsirolimus in humans, also exhibits mTOR in
Publikováno v:
Forensic science international. 210(1-3)
AIM: To estimate the prevalence of driving with blood drug concentrations above the recently proposed Norwegian legal limits for drugged driving in random traffic. The results from a roadside survey of 10,816 drivers was used as basis for the estimat
Autor:
Siddhartha Ganguly, Joseph P. McGuirk, Omar S. Aljitawi, J.D. Pipkin, Sunil Abhyankar, Anna Ludlow, Tara L. Lin
Publikováno v:
Blood. 120:4551-4551
Abstract 4551 Background: In a recent phase IIa open-label, randomized, cross-over design study, we evaluated the pharmacokinetics of Propylene Glycol-Free Melphalan (PG-free Mel) HCL and Alkeran in multiple myeloma patients undergoing transplantatio
Autor:
D. H. Van Thiel, J. J. Fung, Thomas E. Starzl, Howard R. Doyle, Jerry McCauley, John McMichael, Angus W. Thomson, R. Lieberman
Publikováno v:
Therapeutic drug monitoring. 15(6)
A randomized concentration-controlled clinical trial (RCCCT) is an alternate experimental design to the standard dose-controlled study. In a RCCCT, patients are randomly assigned to predefined plasma or blood drug concentration ranges (low, medium, a